Insmed (NASDAQ:INSM) Posts Earnings Results, Beats Expectations By $0.61 EPS

09 Aug 2026, 01:40 by Tristan Rich · The Markets Daily

Insmed (NASDAQ:INSM – Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.67) by $0.61, FiscalAI reports. The company had revenue of $425.49 million for the quarter, compared to analyst estimates of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 122.43%. The firm’s quarterly revenue was up 296.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.70) EPS.

Here are the key takeaways from Insmed’s conference call:

BRINSUPRI launch momentum accelerated: Second-quarter revenue reached $309.2 million, up 49% sequentially, with approximately 7,000 new patient starts and more than 6,300 cumulative prescribers. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion–$1.4 billion from above $1 billion.
Insmed increased its estimated global peak sales opportunity for BRINSUPRI to more than $7 billion, citing expanding diagnosis, strong persistence and payer access, and the potential for broader use among patients with comorbid COPD or asthma. The company said prescribing depth and refill behavior are tracking at or ahead of internal expectations.
TPIP data strengthened the company’s confidence in its pipeline centerpiece. In a 12-month PAH open-label extension, patients maintained or improved efficacy measures, 65% reached refined low-risk status, treatment continuation was 91%, and no new safety signals emerged; Phase III programs in PAH and PH-ILD are enrolling, with PPF and IPF studies planned.
ARIKAYCE revenue rose 8% year over year to $116.3 million, while Insmed reiterated 2026 guidance of $450 million–$470 million. The company has submitted for a U.S. label expansion into newly diagnosed MAC lung disease and expects a Japanese submission in the second half of 2026, potentially supporting launches in 2027.
Insmed reported approximately $1.2 billion in cash and reiterated expectations for cash-flow positivity in 2027 without additional capital raises, despite planned investment in TPIP Phase III trials, BRINSUPRI advertising, and Japanese commercial infrastructure. Management also noted that European commercialization is less attractive because of budget constraints and limited willingness to pay for innovation.

Insmed Trading Down 1.1%

INSM traded down $1.45 during trading on Friday, hitting $131.10. 4,904,073 shares of the stock traded hands, compared to its average volume of 3,072,772. The firm has a market capitalization of $28.42 billion, a P/E ratio of -31.90 and a beta of 0.81. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. The firm has a 50-day moving average of $105.14 and a 200 day moving average of $129.23. Insmed has a 12-month low of $90.39 and a 12-month high of $212.75.

Analyst Ratings Changes

Several research firms have issued reports on INSM. BMO Capital Markets assumed coverage on shares of Insmed in a research report on Monday, July 20th. They set an “outperform” rating and a $192.00 price target for the company. Royal Bank Of Canada decreased their price objective on Insmed from $205.00 to $195.00 and set an “outperform” rating on the stock in a report on Friday, June 5th. Guggenheim lowered their target price on Insmed from $207.00 to $205.00 and set a “buy” rating for the company in a research note on Friday. Truist Financial lowered their target price on Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $235.00 target price on shares of Insmed in a report on Tuesday, July 28th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $205.26.

View Our Latest Research Report on Insmed

More Insmed News

Here are the key news stories impacting Insmed this week:

Positive Sentiment: BRINSUPRI sales significantly exceeded expectations. Second-quarter revenue reached $309.2 million, up 49% from the first quarter, reflecting strong commercial uptake of the company’s bronchiectasis treatment. Insmed raised 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.40 billion and increased its peak-sales estimate to more than $7 billion. Insmed Second-Quarter 2026 Results
Positive Sentiment: Insmed beat quarterly estimates. Total revenue was $425.5 million, up 296.1% year over year and above the approximately $393.7 million consensus forecast. The company reported a loss of $0.06 per share, substantially narrower than the expected $0.67 loss and the $1.70 loss recorded a year earlier. Insmed Tops Q2 Earnings Estimates
Positive Sentiment: Long-term growth expectations improved. Insmed lifted its combined peak-revenue outlook for BRINSUPRI, TPIP and ARIKAYCE to more than $14 billion, including over $6 billion for TPIP. It maintained 2026 ARIKAYCE revenue guidance of $450 million-$470 million and provided total 2026 revenue guidance of approximately $1.7 billion-$1.9 billion.
Positive Sentiment: Trading activity signaled strong investor interest. Call-option volume rose roughly 469% above average, while reports described the stock as gaining about 30%-34% following the earnings release. Analysts also maintained an overall “Buy” recommendation.
Neutral Sentiment: Profitability remains limited. Despite the improved loss, Insmed continues to report negative net income and return on equity as it invests in developing and commercializing its pipeline.

Insider Activity

In other news, insider Michael Alexander Smith sold 1,806 shares of the company’s stock in a transaction dated Monday, June 22nd. The shares were sold at an average price of $95.82, for a total transaction of $173,050.92. Following the completion of the transaction, the insider directly owned 37,648 shares of the company’s stock, valued at approximately $3,607,431.36. This represents a 4.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO William Lewis sold 10,699 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $117.40, for a total transaction of $1,256,062.60. Following the sale, the chief executive officer owned 259,058 shares of the company’s stock, valued at approximately $30,413,409.20. This represents a 3.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 54,590 shares of company stock worth $5,793,738 in the last quarter. Insiders own 2.10% of the company’s stock.

Institutional Trading of Insmed

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INSM. CIBC Private Wealth Group LLC lifted its position in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 53 shares during the period. Raiffeisen Bank International AG purchased a new stake in shares of Insmed in the 4th quarter worth about $32,000. Towarzystwo Funduszy Inwestycyjnych PZU SA purchased a new stake in shares of Insmed in the 4th quarter worth about $49,000. Summit Securities Group LLC bought a new position in shares of Insmed in the 4th quarter worth about $57,000. Finally, Transamerica Financial Advisors LLC increased its stake in shares of Insmed by 72.3% in the 4th quarter. Transamerica Financial Advisors LLC now owns 348 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 146 shares in the last quarter.

About Insmed

(Get Free Report)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.